Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS7415 in Advanced Malignant Tumors
NCT05318833Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS7415 in cancer, sponsored by Hengrui. Primary endpoints: Dose-limiting toxicity at 10 months, Maximum tolerated dose at 10 months and 1 more. Started May 2022; status: completed.
02
Drugs
HRS7415
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05318833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318833.